Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25464172 | 0.83 | SSTR4 (0.44) | L3MBTL1SSTR4HPGDTAS1R3TAS1R1 | |
| SCHEMBL25464188 | 0.82 | KMT2A (0.47) | SSTR4EPHX2HPGDSSTR1KMT2A | |
| SCHEMBL25464178 | 0.81 | EPHX2 (0.43) | SSTR4EPHX2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL25460803 | 0.80 | GAA (0.41) | KDM4ERAB9AALDH1A1 | |
| SCHEMBL25464108 | 0.77 | TAS1R3 (0.47) | L3MBTL1SSTR4EPHX2HPGDTAS1R3 | |
| SCHEMBL1626654 | 0.74 | CES2 (0.44) | HPGD | |
| SCHEMBL30501842 | 0.74 | CES2 (0.44) | HPGD | |
| SCHEMBL25301048 | 0.73 | PLCG1 (0.47) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL3860550 | 0.73 | KCNN4 (0.46) | HPGDKMT2A | |
| SCHEMBL26238626 | 0.72 | HSD11B1 (0.45) | SSTR4KMT2ARAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | L3MBTL1 2173/4885SSTR4 82/4885EPHX2 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.